<?xml version="1.0" encoding="UTF-8"?>
<p>Zika virus infection usually causes mild symptoms, such as rash, fever, headache, and joint pain, but severe symptoms in some cases, such as Guillain-Barré syndrome, meningo-encephalitis and myelitis. ZIKV infection of pregnant women may cause microcephaly in their fetuses and newborns (
 <xref rid="B39" ref-type="bibr">Cui et al., 2017</xref>; 
 <xref rid="B40" ref-type="bibr">Culshaw et al., 2018</xref>). Currently, with repurposing approaches, several FDA-approved drugs with anti-ZIKV activities have been identified, such as Sofosbuvir (
 <xref rid="B155" ref-type="bibr">Xu et al., 2016</xref>), but no drug has been licensed for clinical use (
 <xref rid="B148" ref-type="bibr">Wang et al., 2017</xref>; 
 <xref rid="B71" ref-type="bibr">Han and Mesplede, 2018</xref>). Four serotypes of DENV (DENV-1, 2, 3, and 4) constitute the primary mosquito-borne viral pathogen. DENV is endemic in more than 100 countries worldwide, and infects ∼390 million people each year, of which 96 million people exhibit disease symptoms (
 <xref rid="B16" ref-type="bibr">Bhatt et al., 2013</xref>). After DENV infection, some individuals exhibit mild symptoms like flu, while others might suffer from more severe diseases, such as dengue hemorrhagic fever and shock syndrome (DHF/DSS) (
 <xref rid="B70" ref-type="bibr">Halstead, 2007</xref>). Till now, only several small molecule anti-DENV drugs such as UV-4B (
 <xref rid="B149" ref-type="bibr">Warfield et al., 2016</xref>) have entered Phase I or Phase II clinical trials (
 <xref rid="B143" ref-type="bibr">Tian et al., 2018</xref>), and no specific anti-DENV drugs have been approved for clinical use yet.
</p>
